Cancer Therapy

CXCR-4 clinical antibodies identified

Published in Drug Week, August 1st, 2003

Northwest Biotherapeutics, Inc., (NWBT) announced the completion of its in-vitro preclinical assessment of a battery of proprietary monoclonal antibodies directed against the cancer associated target CXCR-4.

Two of the studied antibodies inhibited tumor cell division and exhibited other anticancer properties.

NWBT scientists were the first to discover that CXCR-4 is over-expressed in cancer. The original findings showed CXCR-4 detectable in glioblastoma and breast cancer tissue but not measurable in normal counterpart tissue. These findings formed the basis for company patent applications filed in early 1998. Subsequently, CXCR-4 has been identified...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-08-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry